1. Home
  2. IPAR vs ACAD Comparison

IPAR vs ACAD Comparison

Compare IPAR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inter Parfums Inc.

IPAR

Inter Parfums Inc.

HOLD

Current Price

$116.81

Market Cap

3.8B

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$28.89

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPAR
ACAD
Founded
1982
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.3B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
IPAR
ACAD
Price
$116.81
$28.89
Analyst Decision
Strong Buy
Buy
Analyst Count
5
22
Target Price
$116.60
$30.55
AVG Volume (30 Days)
228.7K
1.7M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
3.54%
N/A
EPS Growth
2.34
69.12
EPS
2.31
0.20
Revenue
$1,317,700,000.00
$726,437,000.00
Revenue This Year
$3.86
$18.80
Revenue Next Year
$7.89
$11.70
P/E Ratio
$50.84
$144.55
Revenue Growth
21.26
40.45
52 Week Low
$77.21
$19.69
52 Week High
$129.29
$30.96

Technical Indicators

Market Signals
Indicator
IPAR
ACAD
Relative Strength Index (RSI) 48.09 53.08
Support Level $115.59 $27.90
Resistance Level $124.64 $30.96
Average True Range (ATR) 3.51 0.86
MACD -0.08 -0.23
Stochastic Oscillator 61.30 29.41

Price Performance

Historical Comparison
IPAR
ACAD

About IPAR Inter Parfums Inc.

Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: